Andrea Rossi, DO
Neurology · Rochester Hills, MINPI 1932321635
Payments from drug & device makers
Across 1,160 payments — averaging $88.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60K
- Pfizer$16K
- Biohaven Pharmaceuticals, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Novartis$2K
- EMD Serono, Inc.$2K
- plus $11K from 54 others
What the payments were for
- Consulting fees$5,2555%
- Speaking & faculty fees$78,26276%
- Travel & lodging$1,6272%
- Food & beverage$17,68217%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,050 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 92 | $148,087 |
| NuplazidPimavanserin Tartrate | 19 | $98,170 |
| Dimethyl Fumarate | 25 | $58,857 |
| QuliptaAtogepant | 37 | $51,330 |
| Emgality PenGalcanezumab-Gnlm | 56 | $41,869 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $41,330 |
| FingolimodFingolimod Hcl | 17 | $35,110 |
| UbrelvyUbrogepant | 27 | $28,856 |
| KeppraLevetiracetam | 11 | $19,498 |
| ReyvowLasmiditan Succinate | 11 | $15,311 |
| Dalfampridine ErDalfampridine | 24 | $13,489 |
| Carbamazepine ErCarbamazepine | 89 | $11,358 |
| Memantine Hcl | 240 | $7,702 |
| Pyridostigmine Bromide | 29 | $6,966 |
| Gabapentin | 296 | $6,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $15,942 | $148,08792 claims |
| Acadia Pharmaceuticals IncNuplazid | $88 | $98,17019 claims |
| AbbVieQulipta, Ubrelvy | $60,095 | $80,18664 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $105 | $41,33025 claims |
| Lilly USA, LLCReyvow | $92 | $15,31111 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $202 | $8,35343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.
Other neurology in Rochester Hills
- Esther YoungRochester Hills$612K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.